. 2016 Nov 21;12:259. doi: 10.1186/s12917-016-0888-0

Table 1.

Results of PRRSV Ab ELISAs at the sampling points, number of positive animals

Study day	-33	0	3	7	10	14
	n = 10	n = 10	n = 10	n = 10	n = 10	n = 10
Group V
IDEXX	0	0^b	0^b	0^b	8^a,b	10^a
INgezim	0	9^a	7^a	10^a	10^a	10^a
HIPRA A/S	0	2^b	2^b	1^b	5^b	5^b
HIPRA E/S	0	0^b	0^b	0^b	2^c	2^c
QIAGEN	0	0^b	0^b	0^b	8^a,b	10^a
AJ	0	0^b	0^b	2^b	7^a,b	8^a,b
Group N
IDEXX	0	0	0	0	7^b,c	9^a
INgezim	0	1	0	0	10^a,b	10^a
HIPRA A/S	0	0	0	0	0^c	3^b,c
HIPRA E/S	0	0	0	0	0^c	0^c
QIAGEN	0	0	0	0	4^c	9^a
AJ	0	0	0	0	1^c	6^a,b

Group V: vaccination with an inactivated PRRSV type 1 vaccine on days -33 and -19

Groups V and N: intradermal application of an HP PRRSV field strain on day 0

Different letters indicate significant differences between the ELISAs in each group on each sampling point